Transcript Document

ASCO Annual Meeting 2013
Poster presentation
January 2013
1
TARGIT-A trial: Updated results for local recurrence
and survival for the German centers
Presenter: Frederik K. Wenz
5 years results:
• 734 patients, 7 centres in Germany
• Absolute number of events in TARGIT vs. EBRT :
• Primary outcome: IBR 4 vs. 1
• Exploratory outcome: All recurrences (breast
+axilla+contralateral+distant recurrence) 11 vs. 7
• Secondary outcome:
• All deaths 6 vs. 12
• Breast Cancer deaths 3 vs. 5
• Non-Breast Cancer deaths 3 vs. 7
Message:
• The 734 German patients have excellent 5 year outcomes
in both arms of the trial
• Survival was better in TARGIT than in EBRT
Source: J Clin Oncol 31, 2013 (suppl; abstr 1121)
January 2013
2
Intraoperative versus external beam boost for breast
cancer: A matched-pair analysis
Presenter: Elena Sperk
Matched pair analysis impact on overall survival of IORT boost vs. EBRT boost :
• 370 patients with 53 pairs
• Medium Follow up: 56 month in IORT vs. 6 month in EBRT
• Strong trend towards better overall survival after IORT boost (90.2% vs.
62.3%, p = 0.375)
• IBR 1 vs. 1
Message:
• IORT given as a boost seems to have a positive impact on overall survival in
breast cancer patients after breast conserving surgery
Source: J Clin Oncol 31, 2013 (suppl; abstr 1120)
January 2013
3
Intraoperative radiotherapy in early breast cancer:
400 consecutive patients in one institution
Presenter: Mariana Steiner
Single center experience since 2006 IORT only vs. WBRT in low risk early breast
cancer patients (in patients with high risk tumor characteristics at final
pathology, additional local breast therapy)
• 400 patients
• Medium Follow up: 30 month (43 months in the first 200 patients)
• Seven ipsilateral breast failures (1.7%) and one axillary recurrence were
observed
Message:
• Center concludes that intraoperative radiotherapy using the Intrabeam
system is feasible and may offer an alternative to whole breast RT in low risk
breast cancer patients
• Clinically significant local morbidity rate is low
Source: J Clin Oncol 31, 2013 (suppl; abstr 1108)
January 2013
4
January 2013
5